Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 5/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.38 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 2/20 | 0.36 |
| ▸ | METAP1 | P53582 | 2/20 | 0.36 |
| ▸ | PPID | Q08752 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL133092 | 0.96 | SLC7A5 (0.54) | SLC7A5SLC1A3SLC1A2ALOX15ANPEP | |
| SCHEMBL196637 | 0.96 | SLC7A5 (0.54) | SLC7A5SLC1A3SLC1A2ALOX15ANPEP | |
| SCHEMBL839402 | 0.96 | SLC7A5 (0.54) | SLC7A5SLC1A3SLC1A2ALOX15ANPEP | |
| Hydrochloric Acid SCHEMBL10887590 | 0.94 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2ALOX15ANPEP | |
| Hydrochloric Acid SCHEMBL818970 | 0.94 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2ALOX15ANPEP | |
| Hydrochloric Acid SCHEMBL133091 | 0.94 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2ALOX15ANPEP | |
| SCHEMBL10866196 | 0.90 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2ALOX15ANPEP | |
| Sulfuric Acid SCHEMBL28734782 | 0.88 | SLC7A5 (0.47) | SLC7A5SLC1A3SLC1A2ALOX15ANPEP | |
| Phosphoric Acid SCHEMBL28734810 | 0.88 | SLC7A5 (0.47) | SLC7A5SLC1A3SLC1A2ALOX15ANPEP | |
| SCHEMBL4909358 | 0.86 | SLC7A5 (0.45) | SLC7A5SLC1A3SLC1A2ALOX15ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106349156-B | It can be used as the pyridine -2- amides of CB2 agonist | 霍夫曼-拉罗奇有限公司 | 2018-12-11 | — | — | CN | disclosed |
| EP-3072886-B1 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2018-04-18 | — | — | EP | disclosed |
| CN-106349156-A | Pyridine-2-amides capable of being used as CB2 agonist | 霍夫曼-拉罗奇有限公司 | 2017-01-25 | — | — | CN | disclosed |
| EP-3072886-A1 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2016-09-28 | — | — | EP | disclosed |
| EP-2718266-B9 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-09-28 | — | — | EP | disclosed |
| EP-2718266-B1 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-20160137606-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (US) | 2016-05-19 | — | — | US | disclosed |
| US-9321727-B2 | Pyridine derivatives as agonists of the CB2 receptor | HOFFMANN-LA ROCHE INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9290451-B2 | — | — | 2016-03-22 | — | — | US | disclosed |
| EP-2718266-A1 | PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012168350-A1 | PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120316147-A1 | NOVEL PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | US | disclosed |
| EP-1161480-B1 | BIODEGRADABLE AND THERMOSENSITIVE POLYPHOSPHAZENES AND THEIR PREPARATION METHOD | KOREA INST SCI & TECH (KR) | 2004-12-22 | — | — | EP | disclosed |
| EP-1161480-A1 | BIODEGRADABLE AND THERMOSENSITIVE POLYPHOSPHAZENES AND THEIR PREPARATION METHOD | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2001-12-12 | — | — | EP | disclosed |
| US-6319984-B1 | TEMPERATURE-SENSITIVITY AND BIODEGRADABILITY CAN BE CONTROLLED AS DESIRED BY SUBSTITUTING POLYDICHLOROPHOSPHAZENE WITH METHOXY HEPTA(ETHYLENE GLYCOL), DEPSIPEPTIDES AND AMINO ACID ESTERS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2001-11-20 | — | — | US | disclosed |
| WO-2001036516-A1 | BIODEGRADABLE AND THERMOSENSITIVE POLYPHOSPHAZENES AND THEIR PREPARATION METHOD | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316147-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS4, NDUFV1 | SLC7A5 2449/4885SLC1A3 2241/4885SLC1A2 1254/4885 |
| US-20160137606-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS4, NDUFV1 | SLC7A5 2449/4885SLC1A3 2241/4885SLC1A2 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.